Dysbiosis in phylogenetically diverse species associated with type 2 diabetes
Jun 26, 2024
Within-species phylogenetic diversity was identified for strains of 27 species that explain inter-individual differences in type 2 diabetes risk.
Endocrine Society, June 1-4
Jun 20, 2024
The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
Prevalence of cardiovascular risk factors, diseases set to increase
Jun 06, 2024
The annual inflation-adjusted health care costs of cardiovascular risk factors is projected to triple between 2020 and 2050.
Semaglutide cuts risk for kidney outcomes, death in CKD with T2DM
May 31, 2024
A reduction was seen in risk for clinically important kidney outcomes and death from cardiovascular causes.
Coverage for Medicare’s e-visits still available, though few patients use service
By
Kristen Fischer
Apr 16, 2024
E-visits, which drew expanded coverage during the pandemic still are available but not used often, a new study shows.
2011 to 2020 saw increase in annual prescription meds expenditures
Apr 15, 2024
Metabolic agents were the most costly category; antidiabetic agents were the mostly costly therapeutic area.
Major drug companies agree to price negotiations with US government
Oct 03, 2023
Ten drugs have been chosen for price negotiations by the Centers for Medicare & Medicaid Services.
With new model, CMS opens up home care opportunities for MCOs serving dual eligibles
By
Joe Jancsurak
Dec 21, 2020
The Centers for Medicare & Medicaid Services’ new model for 2021 enables Medicaid managed care organizations to allow in-home aides to promote flu vaccines, manage medical appointments and receive training...
Advocacy group alleges PDGM is ‘discriminatory’ policy
By
Diane Eastabrook
Mar 05, 2021
The Center for Medicare Advocacy (CMA) accused the Centers for Medicare and Medicaid Services (CMS) on Thursday of using unfair practices against beneficiaries requiring longer-term home healthcare.
Sanofi follows Lilly, Novo Nordisk in cutting insulin prices
Mar 17, 2023
Sanofi is the third company to cut prices on its insulin products and cap out-of-pocket charges to $35 a month.